Perkins Jennifer M, Davis Stephen N
Division of Diabetes, Endocrinology and Metabolism, Mark Collie Professor of Medicine, Molecular Physiology and Biophysics, Vanderbilt University, 7465 MRB IV, Nashville, TN 37232-0475, USA.
Curr Diab Rep. 2008 Feb;8(1):12-9. doi: 10.1007/s11892-008-0004-3.
The endocannabinoid system (ECS) plays a physiologic role in modulating energy balance, feeding behavior, lipoprotein metabolism, insulin sensitivity, and glucose homeostasis, which when dysregulated can all contribute to cardiometabolic risk. Evidence has suggested that the ECS is overactive in human obesity and in animal models of genetic and diet-induced obesity. ECS stimulation centrally and peripherally drives metabolic processes that mimic the metabolic syndrome. These findings have led to the development of potential novel therapeutic targets, including the drug rimonabant, a selective CB1 receptor antagonist, which has been shown to promote weight loss, reduce inflammation, improve dyslipidemia, and improve glucose homeostasis.
内源性大麻素系统（ECS）在调节能量平衡、进食行为、脂蛋白代谢、胰岛素敏感性和葡萄糖稳态方面发挥着生理作用，当这些调节失调时，都可能导致心脏代谢风险。有证据表明，ECS在人类肥胖以及遗传和饮食诱导的肥胖动物模型中过度活跃。ECS在中枢和外周的刺激会驱动类似于代谢综合征的代谢过程。这些发现促使了潜在新治疗靶点的开发，包括药物利莫那班，一种选择性CB1受体拮抗剂，已证明其可促进体重减轻、减轻炎症、改善血脂异常并改善葡萄糖稳态。
